-
Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug HSK21542, aimed at treating chronic pruritus. Understanding the Impact of Chronic PruritusPruritus, or itching, is an unpleasant sensation…
-
ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for Phase I dosage escalation studies for both IMM2510 and IMM27M, with the recommended Phase II dosage (RP2D) determined for each. IMM2510: A PD-L1/VEGF Bispecific Antibody for Solid TumorsIMM2510, a PD-L1/VEGF bispecific antibody (BsAb) based on…
-
CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
•
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy VSA001, Sperogenix Therapeutics’ vamorolone, and Zai Lab’s (HKG: 9688) efgartigimod are on track for breakthrough therapy designation (BTD) status awards in China. VSA001 for Familial Chylomicronemia Syndrome (FCS)VSA001 is designed to reduce triglyceride levels in…
-
Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to acquire a 9.45% stake in start-up biopharma company Shanghai Anlingke Biopharmaceutical Co., Ltd for a consideration of RMB 30.6 million. This strategic acquisition is set to be completed through the transfer of two cancer therapy…
-
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), is set to fully acquire Fibernova Holding Corporation for a total consideration of USD 2.7 million. The acquisition includes a USD 1.7 million equity exchange…
-
Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-house developed MemoSorb biodegradable patent foramen ovale occluder. This innovative device is now approved for use in patients aged 18 to 60 with…
-
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
•
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies…
-
GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline
•
China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB 400 million (USD 54.8 million). The round was led by CICC, with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership, and existing investors Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.…
ADC / XDC AstraZeneca Auto-immune AZ Biosimilars Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
